Teachers Retirement System of The State of Kentucky grew its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 7.7% in the third quarter, Holdings Channel.com reports. The fund owned 343,501 shares of the company’s stock after buying an additional 24,700 shares during the period. AbbVie makes up approximately 0.6% of Teachers Retirement System of The State of Kentucky’s investment portfolio, making the stock its 21st largest position. Teachers Retirement System of The State of Kentucky’s holdings in AbbVie were worth $89,857,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in ABBV. Financial Freedom LLC acquired a new position in AbbVie in the third quarter worth $29,000. Burk Holdings LLC bought a new stake in AbbVie during the second quarter valued at $30,000. Marquette Asset Management LLC increased its stake in AbbVie by 52.2% during the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after purchasing an additional 48 shares during the last quarter. IMG Wealth Management Inc. increased its stake in AbbVie by 3,060.0% during the second quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock valued at $40,000 after purchasing an additional 153 shares during the last quarter. Finally, Principia Wealth Advisory LLC raised its holdings in shares of AbbVie by 38.9% during the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock worth $40,000 after purchasing an additional 44 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling at AbbVie
In related news, EVP Jeffrey Stewart sold 40,619 shares of AbbVie stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $293.60, for a total value of $11,925,738.40. Following the sale, the executive vice president directly owned 83,171 shares in the company, valued at $24,419,005.60. This trade represents a 32.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.06% of the stock is currently owned by company insiders.
AbbVie Price Performance
Shares of ABBV opened at $294.18 on Tuesday. The company has a market cap of $520.00 billion, a P/E ratio of 50.63, a PEG ratio of 1.34 and a beta of 0.20. The stock has a fifty day moving average price of $276.27 and a 200 day moving average price of $241.28. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $302.93.
AbbVie (NYSE:ABBV – Get Free Report) last issued its earnings results on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, topping the consensus estimate of $3.73 by $0.09. The firm had revenue of $17.40 billion for the quarter, compared to analyst estimates of $17.32 billion. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period last year, the company earned $1.86 earnings per share. As a group, research analysts anticipate that AbbVie Inc. will post 13.98 earnings per share for the current year.
AbbVie Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Stockholders of record on Friday, January 15th will be given a dividend of $1.82 per share. This is an increase from AbbVie’s previous quarterly dividend of $1.73. This represents a $7.28 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Friday, January 15th. AbbVie’s payout ratio is currently 125.30%.
Analyst Ratings Changes
Several research analysts have recently commented on the stock. Oppenheimer lifted their price target on shares of AbbVie from $244.00 to $258.00 and gave the company a “neutral” rating in a report on Monday, August 3rd. Bank of America reaffirmed a “buy” rating on shares of AbbVie in a research report on Tuesday, September 8th. Erste Group Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday, August 5th. Guggenheim raised their target price on shares of AbbVie from $288.00 to $322.00 and gave the stock a “buy” rating in a report on Monday, November 2nd. Finally, BNP Paribas Exane lifted their target price on AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research note on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $297.85.
Get Our Latest Stock Report on AbbVie
AbbVie Profile
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.
Featured Stories
- Five stocks we like better than AbbVie
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
